This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010; 55: 560-578.2010146310.1007/s10620-009-1081-0LewisJRMohantySRNonalcoholic fatty liver disease: a review and updateDig Dis Sci20105556057820101463Search in Google Scholar
Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001; 121:710-23.10.1053/gast.2001.2712611522755ReidAENonalcoholic steatohepatitisGastroenterology20011217102311522755Open DOISearch in Google Scholar
Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non alcoholic fatty liver disease. J Hepatol. 2004; 40: 578-84.15030972CaldwellSHCrespoDMThe spectrum expanded: cryptogenic cirrhosis and the natural history of non alcoholic fatty liver diseaseJ Hepatol2004405788410.1016/j.jhep.2004.02.01315030972Search in Google Scholar
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37:917-23.1266898710.1053/jhep.2003.50161MarchesiniGBugianesiEForlaniGCerrelliFLenziMManiniRet alNonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeHepatology2003379172312668987Search in Google Scholar
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142:1592-609.10.1053/j.gastro.2012.04.001ChalasaniNYounossiZLavineJEDiehlAMBruntEMCusiKet alThe diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of GastroenterologyGastroenterology2012142159260922656328Open DOISearch in Google Scholar
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9:428-33.10.1016/j.cgh.2011.01.02321320639YasuiKHashimotoEKomorizonoYKoikeKAriiSImaiYet alCharacteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinomaClin Gastroenterol Hepatol201194283321320639Open DOISearch in Google Scholar
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-21.10.1002/hep.2070115915461KleinerDEBruntEMVan NattaMBehlingCContosMJCummingsOWet alDesign and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology20054113132115915461Open DOISearch in Google Scholar
Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther. 2011; 34:214-8.10.1111/j.1365-2036.2011.04695.x21585409HjelkremMStauchCShawJHarrisonSAValidation of the non-alcoholic fatty liver disease activity scoreAliment Pharmacol Ther201134214821585409Open DOISearch in Google Scholar
Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128:1898-1906.1594062510.1053/j.gastro.2005.03.084RatziuVCharlotteFHeurtierAGombertSGiralPBruckertEet alSampling variability of liver biopsy in nonalcoholic fatty liver diseaseGastroenterology20051281898190615940625Search in Google Scholar
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49:1017-44.10.1002/hep.2274219243014RockeyDCCaldwellSHGoodmanZDNelsonRCSmithADLiver biopsyHepatology20094910174419243014Open DOISearch in Google Scholar
Musso G, Gambino R, Cassader M, Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med. 2011; 43: 617-49.10.3109/07853890.2010.518623MussoGGambinoRCassaderMPaganoGMetaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severityAnn Med2011436174921039302Open DOISearch in Google Scholar
Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012; 13: 239-50.10.1038/nrm331322436747RottiersVNaarAMMicroRNAs in metabolism and metabolic disordersNat Rev Mol Cell Biol20121323950402139922436747Open DOISearch in Google Scholar
Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology. 2012; 142:1431-43.10.1053/j.gastro.2012.04.00722504185WangXWHeegaardNHOrumHMicroRNAs in liver diseaseGastroenterology2012142143143631110422504185Open DOISearch in Google Scholar
Bala S, Marcos M, Szabo G. Emerging role of microRNAs in liver diseases. World J Gastroenterol. 2009; 15: 5633-40.10.3748/wjg.15.563319960558BalaSMarcosMSzaboGEmerging role of microRNAs in liver diseasesWorld J Gastroenterol200915563340278921419960558Open DOISearch in Google Scholar
Ceccarelli S, Panera N, Gnani D, Nobili V. Dual role of microRNAs in NAFLD. Int J Mol Sci. 2013; 14:8437-55.10.3390/ijms1404843723594995CeccarelliSPaneraNGnaniDNobiliVDual role of microRNAs in NAFLDInt J Mol Sci201314843755364575323594995Open DOISearch in Google Scholar
Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, et al. miR-34a/SIRT1/ p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013; 58: 119-25.2290255010.1016/j.jhep.2012.08.008CastroREFerreiraDMAfonsoMBBorralhoPMMachadoMVCortez-PintoHet almiR-34a/SIRT1/ p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver diseaseJ Hepatol2013581192522902550Search in Google Scholar
Wong MY, Yu Y, Walsh WR, Yang JL. microRNA-34 family and treatment of cancers with mutant or wildtype p53 (Review). Int J Oncol. 2011; 38:1189-95.WongMYYuYWalshWRYangJLmicroRNA-34 family and treatment of cancers with mutant or wildtype p53 (Review)Int J Oncol201138118995Search in Google Scholar
Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012; 15:665-74.2256021910.1016/j.cmet.2012.04.004MinHKKapoorAFuchsMMirshahiFZhouHMaherJet alIncreased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver diseaseCell Metab20121566574336191122560219Search in Google Scholar
Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013; 424:99-103.2372703010.1016/j.cca.2013.05.021YamadaHSuzukiKIchinoNAndoYSawadaAOsakabeKet alAssociations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liverClin Chim Acta20134249910323727030Search in Google Scholar
Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011; 6:e23937.10.1371/journal.pone.002393721886843CermelliSRuggieriAMarreroJAIoannouGNBerettaLCirculating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver diseasePLoS One20116e23937316033721886843Open DOISearch in Google Scholar
Ortega FJ, Mercader JM, Catalan V, Moreno-Navarrete JM, Pueyo N, Sabater M, et al. Targeting the circulating microRNA signature of obesity. Clin Chem. 2013; 59: 781-92.10.1373/clinchem.2012.19577623396142OrtegaFJMercaderJMCatalanVMoreno-NavarreteJMPueyoNSabaterMet alTargeting the circulating microRNA signature of obesityClin Chem2013597819223396142Open DOISearch in Google Scholar
Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: noninvasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014; 39:254-69.10.1111/apt.12569KwokRTseYKWongGLHaYLeeAUNguMCet alSystematic review with meta-analysis: noninvasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragmentsAliment Pharmacol Ther2014392546924308774Open DOISearch in Google Scholar
Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006; 3:87-98.1645931010.1016/j.cmet.2006.01.005EsauCDavisSMurraySFYuXXPandeySKPearMet almiR-122 regulation of lipid metabolism revealed by in vivo antisense targetingCell Metab20063879816459310Search in Google Scholar
Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008; 36: 1153-62.10.1093/nar/gkm111318158304ElmenJLindowMSilahtarogluABakMChristensenMLind-ThomsenAet alAntagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liverNucleic Acids Res200836115362227509518158304Open DOISearch in Google Scholar
Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and antitumorigenic functions of miR-122 in liver. J Clin Invest. 2012; 122:2871-83.10.1172/JCI63539HsuSHWangBKotaJYuJCostineanSKutayHet alEssential metabolic, anti-inflammatory, and antitumorigenic functions of miR-122 in liverJ Clin Invest2012122287183340874822820288Open DOISearch in Google Scholar
Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122:2884-97.10.1172/JCI63455TsaiWCHsuSDHsuCSLaiTCChenSJShenRet alMicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesisJ Clin Invest2012122288497340874722820290Open DOISearch in Google Scholar
